Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBT Margin (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBT Margin readings, the most recent being 6.49% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 2445.0% to 6.49% in Q4 2025 year-over-year; TTM through Dec 2025 was 14.81%, a 1197.0% decrease, with the full-year FY2025 number at 14.81%, down 1197.0% from a year prior.
  • EBT Margin hit 6.49% in Q4 2025 for Cytek Biosciences, up from 14.86% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 17.96% in Q4 2024 to a low of 27.18% in Q1 2025.
  • Median EBT Margin over the past 5 years was 4.99% (2025), compared with a mean of 5.14%.
  • Biggest five-year swings in EBT Margin: surged 1202bps in 2021 and later tumbled -2445bps in 2025.
  • Cytek Biosciences' EBT Margin stood at 0.51% in 2021, then surged by 1765bps to 8.51% in 2022, then decreased by -17bps to 7.06% in 2023, then surged by 154bps to 17.96% in 2024, then crashed by -136bps to 6.49% in 2025.
  • The last three reported values for EBT Margin were 6.49% (Q4 2025), 14.86% (Q3 2025), and 14.86% (Q2 2025) per Business Quant data.